EZH2 and prostate cancer: With regard to TRIM25, its oncogenic potential has been mainly assigned to the modulation of diverse oncogenic signaling pathways, including the Keap1-Nrf2 pathway, which is relevant for liver cancer [47]; the p53-G3BP2 interactions, which are critical for prostate cancer cell growth [48]; or the stabilization of the enhancer of the zeste 2 homologue subunit 2 (EZH2), a critical histone methyl-transferase and epigenetic silencer complex which is relevant for the oxaliplatin resistance of colorectal cancer [49].